Grail price target raised to $43 from $32 at Canaccord

Canaccord raised the firm’s price target on Grail (GRAL) to $43 from $32 and keeps a Buy rating on the shares. The firm updated its model following results and said they remain bullish after a solid 1Q25 update, as they think the company will benefit from upcoming catalysts and its “trailblazer” advantage in multi-cancer early detection (MCED).